BIOGRAPHY
Dr. Lisa A. Beck is an internationally recognized expert in atopic dermatitis (AD), whose research focuses on epithelial abnormalities in AD focusing on their import in allergen sensitization, barrier dysfuction and cutaneous infections. She and Dr. De Benedetto were the first to characterize epidermal tight junction defects in AD. She played a pivotal role in the clinical development of dupilumab (Dupixent), the first biologic approved for moderate-to-severe AD; and was the lead author of the 2014 New England Journal of Medicine publication that helped establish the foundation for FDA approval in 2017. Continuously funded by the NIH since 1994, Dr. Beck has been a member of the NIAID-funded Atopic Dermatitis Research Network (ADRN) since its inception in 1993. She has chaired numerous multicenter clinical and mechanistic studies, including a large AD registry, skin barrier investigations, and studies examining dupilumab's effects on host–microbial interactions. She has published over 150 scientific papers and reviews and held numerous national and international leadership positions, including President of the Society for Investigative Dermatology, Secretary of the International Eczema Council, member of the American Board of Dermatology, and Associate and Section Editor of the Journal of Investigative Dermatology. Her contributions have been recognized through honorary memberships, prestigious named lectureships, and numerous scientific awards.
SESSIONS
DISCLOSURES
AbbVie – Consultant (1099 relationship)(Fees); AMGEN – Consultant (1099 relationship)(Honoraria); Apogee BioPharm – Consultant (1099 relationship)(Honoraria); Arcus Biosciences – Consultant (1099 relationship)(Honoraria); Arcutis Biotherapeutics – Consultant (1099 relationship)(Honoraria); Arena Pharmaceuticals – Consultant (1099 relationship)(No Compensation Received); AstraZeneca – Consultant (1099 relationship)(Fees); Astria Therapeutics – Consultant (1099 relationship)(Honoraria); Bambusa Therapeutics Inc – Consultant (1099 relationship)(Honoraria); Belharra Therapeutics – Consultant (1099 relationship)(Honoraria); Celldex – Consultant (1099 relationship)(Honoraria); Dermavent – Consultant (1099 relationship)(Honoraria); Eli Lilly and Company – Consultant (1099 relationship)(Fees), Consultant (1099 relationship)(Honoraria); Escient Pharmaceuticals, Inc – Consultant (1099 relationship)(Honoraria); Evommune, Inc. – Consultant (1099 relationship)(Honoraria); Galderma Research & Development, LLC – Consultant (1099 relationship)(Honoraria); Gilead Sciences, Inc – Consultant (1099 relationship)(Honoraria); GlaxoSmithKline Immunology – Consultant (1099 relationship)(Honoraria); Invea Therapeutics – Consultant (1099 relationship)(Honoraria); Janssen Pharmaceuticals, Inc – Consultant (1099 relationship)(Honoraria); LEO Laboratories Ltd (LEO Pharma) – Consultant (1099 relationship)(Fees); Medtronics – Stockholder(Stock); Merck & Co., Inc – Consultant (1099 relationship)(Honoraria); Nektar Therapeutics – Consultant (1099 relationship)(Honoraria); Novartis – Consultant (1099 relationship)(Fees); NUMAB Therapeutics AG – Consultant (1099 relationship)(Honoraria); Pfizer Inc. – Consultant (1099 relationship)(Fees); Regeneron – Consultant (1099 relationship)(Fees); Regeneron Pharmaceuticals, Inc. – Investigator(Grants/Research Funding); ResVita Bio, Inc – Consultant (1099 relationship)(Honoraria); Ribon Therapeutics – Consultant(Honoraria); Sanofi – Consultant (1099 relationship)(Fees), Investigator(Grants/Research Funding); Sitryx Therapeutics – Consultant (1099 relationship)(Honoraria); Stealth Biotherapeutics – Consultant (1099 relationship)(Honoraria); TRex Bio – Consultant (1099 relationship)(Honoraria); Triveni Bio – Consultant (1099 relationship)(Honoraria); Tupos Therapeutics – Consultant (1099 relationship)(Honoraria); UCB Pharma – Consultant (1099 relationship)(Honoraria); Union Therapeutics – Consultant (1099 relationship)(Honoraria); Xencor – Consultant (1099 relationship)(Honoraria); Zai Laboratories – Consultant (1099 relationship)(Honoraria);